Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients ; volume:32 ; number:5 ; day:10 ; month:7 ; year:2024 ; pages:3259-3269 ; date:10.2024
Inflammopharmacology ; 32, Heft 5 (10.7.2024), 3259-3269, 10.2024
- Urheber
-
Kamal, Mahmoud E.
Werida, Rehab H.
Radwan, Mahasen A.
Askar, Safaa R.
Omran, Gamal A.
El-Mohamdy, Marwa A.
Hagag, Radwa S.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10787-024-01508-w
- URN
-
urn:nbn:de:101:1-2412160949222.368174402743
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kamal, Mahmoud E.
- Werida, Rehab H.
- Radwan, Mahasen A.
- Askar, Safaa R.
- Omran, Gamal A.
- El-Mohamdy, Marwa A.
- Hagag, Radwa S.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
Infliximab und Adalimumab in der Therapie der Colitis ulcerosa : eine retrospektive Analyse
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
Infliximab und Adalimumab in der Therapie der Colitis ulcerosa : eine retrospektive Analyse
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis
High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
Mapping the certolizumab pegol epitope on TNF and comparison with infliximab, adalimumab and etanercept
Comparison between infliximab and adalimumab in the treatment of perianal fistulas in Crohn's disease
Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease
Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease
Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients
Infliximab und Adalimumab in der Therapie der Colitis ulcerosa : eine retrospektive Analyse